New CAR T-Cell therapy takes aim at tough T-Cell cancers
NCT ID NCT06316856
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 33 times
Summary
This study tests a new treatment called CD5 CAR T-cells for people with T-cell cancers (like certain leukemias) that have returned or not responded to standard care. The treatment uses a patient's own immune cells or cells from a donor, which are modified in a lab to recognize and attack cancer cells. The trial has two phases: first to find a safe dose, then to see how well it shrinks tumors. About 54 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
-
Shanghai Liquan Hospital
RECRUITINGShanghai, Shanghai Municipality, 201418, China
-
The General Hospital of Western Theater Command PLA
NOT_YET_RECRUITINGChengdu, Sichuan, 610083, China
-
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
RECRUITINGShanghai, Shanghai Municipality, 200435, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD5 CAR T-cells (immune cells engineered to target cancer)
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat T-cell cancers that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 54 participants, so results may not apply broadly. CAR T-cell therapy can cause severe side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.